


# DN Update 2023 Spring ADRC Meeting

Jennie Larkin
Deputy Director
DN/NIA

#### NIA-AD from "bench to bedside" toward Precision Medicine






NIA Science Officer: Laurie Ryan Pls: Paul Aisen, Reisa Sperling, Ron Peterson

ACTC conducts clinical trials (Phase I-III) of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric symptoms.

ADRCs provide data, samples, and participants to other studies.



# **ADRC** infrastructure supports NIA research



#### **Directors Office**

#### • Eliezer Masliah (Director) and Jennie Larkin (Deputy Director)

• Jean Tiong-Koehler, Toni Salazar, Donna Weaver, Sarita Chapman, LaKeisha Carroll, Alyssa Lin, Tere Lindquist, Kathy Green, Karyn Onyeneho

#### Leadership team

 Eliezer Masliah, Jennie Larkin, Mack Mackiewicz, Damali Martin, Molly Wagster, Suzana Petanceska, Laurie Ryan, Lorenzo Refolo

# Strategic Development and Partnerships Office

Suzana Petanceska (Director)

 Nadezda Radoja, Erika Tarver, Laurie Ryan, Nandini Arunkumar, Alvin McKelvy, Jaya Viswanathan, Grayson Donley

## Population Studies and Genetics Branch

#### • Damali Martin (Chief)

• Dallas Anderson, Marilyn Miller, Alison Yao, Jennie Larkin, Richard Kwok, Maryam Ghaleh, Sharna Tingle, Camille Pottinger, Tayona Pearson

# **Neurobiology of Aging and Neurodegeneration Branch**

#### Mack Mackiewicz (Chief)

• Paul Barrett, Amanda DiBattista, Maja Maric, Austin Yang, Lisa Opanashuk, Elizabeth Newman, Erin Gray, Rachel Sare, Chelsea Haakenson, Joe Pottackal,

## **Behavioral and Systems Neuroscience Branch**

#### Molly Wagster (Chief)

 Luci Roberts, Coryse St. Hillaire-Clarke, Devon Oskvig, Matt Sutterer, Dave Frankowski, Caroline Sferrazza, Justin Reber

## Translational Research Branch


#### Lorenzo Refolo (Chief)

 Suzana Petanceska, Zane Martin, Nandini Arunkumar, Shreaya Chakroborty, Paul Grothaus, Jennifer Isaacs, Maria Fe LanFranco

# Clinical Interventions and Diagnostics Branch


- Laurie Ryan (Chief)
- Nina Silverberg, John Hsiao, Cerise Elliott, Yuan Luo, Kristina McLinden, Alessandra Rovescalli, Akanni Clarke, Grayson Donley, Alvin McKelvy, Benfeard Williams, Aleksandra Dakic

# Pathogenesis of AD: aging, genetics and environment multiple pathways lead to AD/ADRD





## Contribution of aging mechanisms to AD/ADRD pathogenesis





## Alzheimer's Disease Sequencing Program


100,000 WGS by 2025 includes diverse population

AL/ML

Consortium

# Over 75 risk loci and 20 genes for AD identified

- Examples: BIN1, TREM2, CR1, PCALM, ADAM10, ABCD4, PLGC2, ANAX5, MEF2
- Involved in immune, neuronal & synaptic, endocytosis, lysosome and lipid metabolism
- Common polygenic variation increases risk prediction (APOE+others)



Harmonization: increase usability of ADSP data resources to the community

Phenotype

Harmonization

Consortium

FunGen-AD


Consortium

- AI/ML: identify gene variants that contribute to the risk or protection to AD, across multiple data sources (genetic, genomic, imaging, and phenotypic data)
- Functional Genomics: translate genetic findings into mechanistic insights and therapies

Work Groups across consortia

#### Diversifying the Therapeutic Pipeline and Enabling a Precision Medicine Approach

A Pipeline of Translational Research Funding Opportunities (R21/R01, U01, SBIR/STTR)



ADSP AMP-AD and Affiliated Consortia

**TREAT-AD Centers** 

**10DEL-AD Centers** 

ADNI
AMP-AD Biomarkers
ABC-DS
ACTC

**Enabling Discovery Programs and Infrastructure for Data Driven and Predictive Drug Development** 


## **Active NIA AD/ADRD Clinical Trials**





66 TRIALS



152 TRIALS







For more information please visit www.nia.nih.gov/research/ongoing-AD-trials




#### PRECISION MEDICINE APPROACH TO TREATMENT AND PREVENTION

#### **DISEASE COMPLEXITY**


Multiple Etiologies Multiple Prodromal Phenotypes Multiple Progression Trajectories

RIGHT TARGET
RIGHT PATIENT
RIGHT DRUG/INTERVENTION
RIGHT DOSE
RIGHT STAGE OF DISEASE



### NIA WORKSHOP (December 2020):

Understanding the Role of the Exposome in Brain Aging, Alzheimer's Disease (AD) and AD-Related Dementias



2015 NIH AD Research Summit SESSION THREE: New Strategies for Prevention

2018 NIH AD Research Summit
SESSION FIVE: Understanding the Impact of the Environment to
Advance Disease Prevention

2021 NIH AD Research Summit
SESSION SEVEN: Understanding the Impact of the Exposome on
Brain Health to Advance Disease Prevention

#### Recent approved NIA exposome concepts

- Quantifying the impact of environmental toxicants on AD/ADRD in cohort studies
- Understanding gene-environment interactions in brain aging and AD/ADRD
- Preclinical studies to characterize the impact of toxicants on brain aging and AD/ADRD

Notice of Special Interest (NOSI): Climate Change and Health Administrative Supplements <a href="https://grants.nih.gov/grants/guide/notice-files/not-hd-23-006.html">https://grants.nih.gov/grants/guide/notice-files/not-hd-23-006.html</a>


#### PRECISION ENVIRONMENTAL HEALTH




Precision Environmental Health describes the next-generation of Environmental Health research occurring at the intersection of G (epigenome/genome) perturbations x E (environmental exposures) x D (data-omics i.e. genome, epigenome, metagenome, proteome, metabolome).

scores

scores







# Implementing the NIH Data Management and Sharing (DMS) Policy


# Policy Requirements

**Submission** of Data Management & Sharing Plan with all applications for funding beginning January 25, 2023

Compliance with the Data

Management and Sharing Plan
approved by the funding NIH Institute,
Center, or Office

## Elements of a DMS Plan



- Data type
  - Identifying data to be preserved and shared
- Related tools, software, code
  - Tools and software needed to access and manipulate data
- Standards
  - Standards to be applied to scientific data and metadata
- Data preservation, access, timelines
  - Repository to be used, persistent unique identifier, and when/ how long data will be available
- Access, distribution, reuse considerations
  - Description of factors for data access, distribution, or reuse
- Oversight of data management and sharing
  - Plan compliance will be monitored/ managed and by whom

## Format of a DMS Plan

- ✓ DMS Plan recommended not to exceed 2 pages in length
- ✓ Optional format page is available
- Check with your program officer

#### DATA MANAGEMENT AND SHARING PLAN

If any of the proposed research in the application involves the generation of scientific data, this application is subject to the NIH Policy for Data Management and Sharing and requires submission of a Data Management and Sharing Plan. If the proposed research in the application will generate large-scale genomic data, the Genomic Data Sharing Policy also applies and should be addressed in this Plan. Refer to the detailed instructions in the application guide for developing this plan as well as to additional guidance on <a href="mailto:should-be-deleted.">sharing.nih.gov</a>. The Plan is recommended not to exceed two pages. Text in italics should be deleted.

#### Element 1: Data Type

A. Types and amount of scientific data expected to be generated in the project:

Summarize the types and estimated amount of scientific data expected to be generated in the project,

B. Scientific data that will be preserved and shared, and the rationale for doing so:

Describe which scientific data from the project will be preserved and shared and provide the rationale for this decision.

C. Metadata, other relevant data, and associated documentation:

Briefly list the metadata, other relevant data, and any associated documentation (e.g., study protocols and data collection instruments) that will be made accessible to facilitate interpretation of the scientific data.

#### Element 2: Related Tools, Software and/or Code:

State whether specialized tools, software, and/or code are needed to access or manipulate shared scientific data, and if so, provide the name(s) of the needed tool(s) and software and specify how they


#### **DMS Plan Format Page**

# Sample DMS Plans on sharing.nih.gov

Sample Plan G 🗹	Human clinical and genomics data	NICHD
Sample Plan H ☑	Gene expression analysis data from non-human model organism (zebrafish)	NICHD
Sample Plan I <sup>™</sup>	Human survey data	NICHD
Sample Plan J <sup>C</sup>	Clinical Data from Human Research Participants	NIDDK

## **DMS Plan Submission**

- A new "Other Plan(s)" field added to the PHS 398 form to collect a single PDF attachment
- Data Sharing Plans and Genomic Data Sharing Plans will no longer be submitted to the "Resource Sharing Plan(s)" field



# BMIC listing of Data Repositories

DOMAIN-SPECIFIC REPOSITORIES

**GENERALIST REPOSITORIES** 

### **Domain-Specific Repositories**

Displaying 1 - 1 of 1 results

CLEAF

ICO	SUBJECTAREA	MODEL SYSTEM	ACCESS TYPE	PI	ROPERTIES
All	✓ All	V All	✓ All	~	All
NIA	Neuroscience	human	registered		Open data submission
					Open timeframe for data deposit
					NIH funding support
					Sustained support
	All	AII ~ AII	All V All V All	All V All V All	All V All V All V

Displaying 1 - 1 of 1 results

PF

# Finding and Selecting a Repository

Recommend using a data-type or discipline-specific repository if available

Look on BMIC Data Repository Listing

Supplemental Information to the NIH Policy for Data Management and Sharing:

Selecting a Repository for Data Resulting from NIH-Supported Research

**Notice Number:** 

NOT-OD-21-016

## Key Dates

Release Date: October 29, 2020

· Generalist repositories

See Selecting a Data Repository for details

























